Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
Positive High overall response rate of 86% in heavily pretreated patients Complete response rate of 55% in patients with treatment options Well-managed safety profile with no unexpected safety signals Successful validation of treatment in multi-center setting
Negative None.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more